Seeking Alpha
View as an RSS Feed

Commander Rydell  

View Commander Rydell's Comments BY TICKER:
Latest  |  Highest rated
  • These 4 Small-Cap Stocks Should Produce Big Gains In 2014 [View article]
    Nice article and especially your coverage of WYY. The recent GAO ruling in favor of WYY adds to the significance of the DHS $600 million contract. Lots of catalysts and growth ahead for this way undervalued company. Thanks for the article.
    Jan 16, 2014. 03:37 PM | 1 Like Like |Link to Comment
  • Implant Sciences: The 30-Year-Old Virgin Grows-Up. [View article]
    Nice article and great opportunity to buy low and sell higher at $2 or $3 imo.
    Jan 1, 2014. 05:53 PM | Likes Like |Link to Comment
  • Pozen Inc: Huge Special Dividend And PDUFA On The Horizon Equal Big Gains [View article]
    Nice job Bob, you hit the nail on the head!
    Nov 21, 2013. 05:09 PM | Likes Like |Link to Comment
  • Cellceutix And Kevetrin Aligning With The Pharmacyclics Growth Curve [View article]
    Nice article. Good luck to the CTIX longs.
    Jul 11, 2013. 11:36 PM | Likes Like |Link to Comment
  • Why Buy Vivus And Arena? Private Insurance, ObamaCare To Cover Their Obesity Drugs [View instapost]
    VIVUS will be a plus $25 dollar a share company because of Obama Care. Patience will pay and by spring time it will become apparent.
    Dec 21, 2012. 08:36 AM | Likes Like |Link to Comment
  • Vivus Rises On Wider Coverage Of Qsymia [View article]
    I strongly suggest to not wait too long to buy VIVUS as the new healthcare law is going to provide motivation to payors to cover Qsymia. Express Scripts is just the beginning. I found this great SA blog by Rex Graham that really spells out the new reality of Obama Care. Unfortunately the epidemic of obesity in this country provides a huge platform for Qsymia to thrive and most people fail on lifestyle and dietary modification. We are in the catbird seat as VIVUS investors:
    Dec 21, 2012. 08:11 AM | 1 Like Like |Link to Comment
  • Vivus, Dendreon Set To Rally From The January Effect [View article]
    "Usually when one of the major health insurers decides to cover a product their competitors also agree to cover a product. Aetna's actions should allow prescriptions for Qsymia to begin to rise."

    It looks like your prediction was spot on as Qsymia is now on Express Script's national formulary. This is a material event that opens the doors for a lot of prescription opportunities. Formulary is 90% of the battle for any new drug and the copay is significantly less than the retail price. Taking a pill to lose weight is a no brainer for the patient that is desperate, has been unsuccessful with lifestyle modification, and wants to avoid surgery. Qsymia sales are going to start to ramp up.
    Dec 20, 2012. 05:17 PM | 1 Like Like |Link to Comment
  • Vivus, Dendreon Set To Rally From The January Effect [View article]
    Nice article. Great timely point about Aetna covering Qsymia and today's Express Script news! Excellent.
    Dec 20, 2012. 12:03 PM | 1 Like Like |Link to Comment
  • Watch Cellceutix Closely For Potential Catalysts In 2013 [View article]
    Nice article Karin! CTIX is going to be one for the ages once the tumor marker data comes out and the non-geno toxic properties are revealed. Here's to the future!
    Dec 10, 2012. 11:37 PM | 1 Like Like |Link to Comment
  • As Galena Teams Up With Teva, Shares Now Possess Some Very Nice Upside Potential [View article]
    It sounds like he is scared and so he is stretching beyond credibility in his commentary. Insecurity in his short position may lead to similar screeches into the future.
    Dec 6, 2012. 12:26 PM | Likes Like |Link to Comment
  • Chinese Chain Pharmacies: Healthy and Growing Industry [View article]
    I'm wondering what your thoughts are on the recent PR's on uplisting from the pinks to the OTCBB? Thank you.
    Dec 1, 2012. 08:49 PM | Likes Like |Link to Comment
  • Simply Put, Longwei Petroleum Worth $6 Or More Per Share [View article]
    Check out the Ihub stickies on the LPH board to get further color on LPH. It's a gem:
    Nov 29, 2012. 08:02 PM | 1 Like Like |Link to Comment
  • Simply Put, Longwei Petroleum Worth $6 Or More Per Share [View article]
    Kevin, fantastic article that points out the grand truth about this company and how undervalued it is.

    One thing I would like to add, Cai Yongju and Yongpin Xue did not accept salaries for fiscal year 2012. This management is above and beyond the model Chinese small cap and will eventually find its value above $6 dollars a share.

    Page 16:

    **The two principle shareholders agreed not to take any compensation from the Company for the year ended June 30, 2012.
    Nov 29, 2012. 07:58 PM | 4 Likes Like |Link to Comment
  • Valeant Is On An Acquisition Spree - Will Prurisol Get Under Big Pharma's Skin? [View article]
    Out licensing for Kevetrin is a distinct possibility and down the road, a topical drug utilizing Kevetrin's active ingredient could be used for a variety of skin cancers, actinic keratosis, and possibly STD's. Efficacy along with the P53 sizzle, and CTIX stock price soars!
    Nov 26, 2012. 08:06 AM | Likes Like |Link to Comment
  • Cellceutix Eyeing A $5B Annual Market With Potential Caner Research Breakthrough [View article]
    The fact that Kevetrin has worked in animal models among a broad range of cancers makes the possibility much higher that Kevetrin will have efficacy in human trials. Phase one secondary endpoints will shine the light on the efficacy question as it seems the safety and maximum dosing questions should be favorably answered.
    Nov 26, 2012. 07:36 AM | 1 Like Like |Link to Comment